Monday, October 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 16, 2026

Barry Silbert Forecasts Up To 10% Of Bitcoin's Market Cap Will Move To Privacy Coins—Crypto Mogul Says Zcash Can Rocket 500x, BTC Won't

View original at finance.yahoo.com
Barry Silbert Forecasts Up To 10% Of Bitcoin's Market Cap Will Move To Privacy Coins—Crypto Mogul Says Zcash Can Rocket 500x, BTC Won't Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Coins such as Zcash have 500x upside potential

    80% confidence

  • Privacy-focused cryptocurrencies are poised to become the next big investment opportunity in the cryptocurrency industry

    80% confidence

  • The recent cryptocurrency crash is a 'gift from the crypto gods' clearing out excess leverage and crap tokens, potentially paving the way for significant capital inflows

    80% confidence

  • Bitcoin lost the plot as an anonymous currency due to the rise of on-chain analytics firms

    80% confidence

  • Bitcoin will not soar 500 times unless the dollar crashes

    80% confidence

  • I am incredibly bullish about Bitcoin as a core part of a diversified portfolio

    80% confidence

  • Bitcoin is likely never going to have any privacy features

    80% confidence

  • I like to invest in projects that I think are transformative

    80% confidence

  • 5-10% of Bitcoin's market cap would rotate into privacy coins, including Zcash

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com